Preterm LaborNCT03253016
The Impact of Cervical Cerclage or Vaginal Progesterone on Vaginal Microbiome Distribution
A study testing vaginal swab -microbiome test and blood test for cytokines in people with Preterm Labor, run by Western Galilee Hospital-Nahariya at 1 site in Israel.
Trial summary
A comparative evaluation to evaluate the correlation between cervical cerclage or vaginal progesterone and maternal vaginal microbiome distribution during pregnancy Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Preterm Labor
- What is being tested?
- vaginal swab -microbiome test and blood test for cytokines
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteIsrael
- Study dates
- 26 Mar 2017to Jan 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- G- roup 1 - Pregnant women with a singleton gestation and cervical cerclage at 12-14 weeks of gestation due to obstetrical history characteristic of cervical insufficiency G- roup 2 - Pregnant women with a singleton gestation at 12-14 weeks of gestation without a history of cervical insufficiency
- Group 3 - Pregnant women treated with progesterone due to previous preterm labor without cerclage
Who cannot join
- A- cute cervical insufficiency P- roven or suspected chorioamnionitis P- remature rupture of membranes F- etal structural abnormality G- estation beyond 15 weeks A- ntibiotic usage in the past month P- robiotic use in the past month R- eported autoimmune disease or immunosuppressive disorder
Trial locations and contacts
1 site in 1 country.
Israel1 site, 1 recruiting
- Recruiting
Galil Medical Center
Nahariya, Israel
Maya Wolf, MD, 972-507887800, homesickid@yahoo.com
About this study
Official title: A Comparative Evaluation to Evaluate the Correlation Between Cervical Cerclage or Vaginal Progesterone and Maternal Vaginal Microbiome Distribution During Pregnancy
A comparative evaluation to evaluate the correlation between cervical cerclage or vaginal progesterone and maternal vaginal microbiome distribution during pregnancy
Read the detailed description
Cervical insufficiency is primarily a clinical diagnosis, characterized by painless cervical dilation leading to recurrent second-trimester pregnancy losses/births of otherwise normal pregnancies.
Adverse perinatal events associated with cervical insufficiency include prolapse of the fetal membranes into the vagina, intra-amniotic infection, preterm premature rupture of membranes, preterm labor and fetal loss.
Congenital and acquired cervical abnormalities increase the risk of cervical insufficiency; Acquired risk factors are more common and include cervical trauma during delivery, rapid mechanical cervical dilation before a gynecologic procedure or treatment of cervical intraepithelial neoplasia (1). Congenital abnormalities include genetic disorders affecting collagen, uterine anomalies and in the past - in utero diethylstilbestrol (DES) exposure (2, 3).
The diagnosis of cervical insufficiency is based on either
- History of painless cervical dilatation with preterm (midtrimester) delivery
- History of prior second-trimester pregnancy losses or preterm births and cervical length ≤25 mm on transvaginal ultrasonography examination or advanced cervical changes on physical examination before 24 weeks of gestation.
The diagnosis of cervical insufficiency is usually limited to singleton gestations. In addition, preterm labor, infection, abruptio placenta, and bleeding placenta previa should be excluded, as these disorders could account for biochemically mediated cervical ripening leading to second-trimester pregnancy loss or preterm delivery independent of structural/anatomic cervical weakness [4].
The American College of Obstetricians and Gynecologists (ACOG) defines cervical insufficiency as the inability of the uterine cervix to retain a pregnancy in the second trimester in the absence of clinical contractions, labor, or both [5].
Women with a history of cervical insufficiency should be considered for history-indicated cerclage in future pregnancies at 12 to 14 weeks of gestation (6, 7).
Cerclage placement is considered a benign proce¬dure, the risks of such procedure include - cervical lacerations at the time of delivery, the need for cesarean delivery because of the inability of the cervix to dilate secondary to cervical scarring and dystocia, infection, cervical cerclage displacement Nonsurgical interventions have been advocated for patients with presumed cervical insufficiency. Progesterone supplementation appears to reduce the rate of spontaneous singleton preterm birth in women who have had a previous spontaneous preterm singleton birth and in women with a short cervix on ultrasound examination in the current pregnancy (8). In women with a prior preterm birth, continuing progesterone supplementation after placement of a cerclage has not been proven to be useful, but available data are limited.
Most cerclages are placed via a transvaginal approach. The transabdominal approach is more invasive, but allows higher placement, while transvaginal cerclages often end up distal to the internal os. The two most common transvaginal techniques for cerclage are McDonald procedure and Shirodkar procedure. The McDonald procedure is easier to perform and remove. The bulk of data show no significant differences in pregnancy outcome between the two procedures (6, 9, 10).
McDonald cerclage -
- The procedure is begun by grasping the anterior and posterior lips of the cervix with one or two ring forceps
- A curved needle loaded with large caliber non-absorbable synthetic suture (at least number 1 or 2 braided or monofilament) is inserted at 12 o'clock, at least 2 cm above the external os.
- Four to six passes of a purse-string suture are taken circumferentially around the entire cervix as high as safely possible.
- The two ends of the suture are then tied securely and cut, leaving the ends long enough to grasp with a clamp when it is time to remove it (11).
During gestation, the female body undergoes hormonal, immunological, and metabolic changes to support fetal growth and development. There are noticeable changes in the microbiota at different body sites during pregnancy.
The human vaginal microbiota is a key component in the defense system against microbial and viral infections. The vaginal microbiome is dominated by many species including Lactobacillus and members of the Clostridiales, Bacteriodales, and Actinomycetales. Specifically, these lactic acid producing bacteria can create a barrier against pathogen invasion by maintaining a low pH (< 4.5) and by secreting metabolites that play an important role in inhibition of bacterial and viral infection in the urogenital tract.
The vaginal microbiome undergoes significant changes during pregnancy, including a significant decrease in overall diversity, increased stability and enrichment with Lactobacillus species (12). These correlate with a decrease in the vaginal pH and an increase in vaginal secretions. Vaginal microbial compositions were found to differ according to gestational age, while the communities at the later stages of pregnancy resembled those of the non-pregnant state. The dominant Lactobacillus species in pregnancy varies according to ethnic group. In women whose vaginal microbiota is not lactobacilli-dominated anti-bacterial defense mechanisms are reduced. The enhanced proliferation of pathogenic bacteria plus degradation of the cervical barrier increase bacterial passage into the endometrium and amniotic cavity and trigger preterm myometrial contractions (13).
About 2 million cervical cerclages are performed annually to prevent preterm birth. Two types of suture material are used for cerclage: monofilament or multifilament braided. Braided sutures are most frequently used, although no evidence exists to favor them over monofilament sutures. Birth outcomes in a retrospective cohort of 678 women receiving cervical cerclage in five UK university hospitals showed that braided cerclage was associated with increased intrauterine death (15% versus 5%; P = 0.0001) and preterm birth (28% versus 17%; P = 0.0006) compared to monofilament suture. A prospective study explored the vaginal microbiome in women at risk of preterm birth because of short cervical length (≤25 mm) who received braided (n = 25) or monofilament (n = 24) cerclage under comparable circumstances (14). Braided suture induced a persistent shift toward vaginal microbiome dysbiosis characterized by reduced Lactobacillus spp. and enrichment of pathobionts. Vaginal dysbiosis was associated with inflammatory cytokine and interstitial collagenase excretion into cervicovaginal fluid and premature cervical remodeling. Monofilament suture had comparatively minimal impact upon the vaginal microbiome and its interactions with the host. The shift of the human vaginal microbiome toward dysbiosis correlated with preterm birth (14).
- Conditions
- Preterm Labor
- Being tested
- vaginal swab -microbiome test and blood test for cytokines
- Medical subject headings
- Obstetric Labor, Premature
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
vaginal swab -microbiome test and blood test for cytokinesDiagnostic test
vaginal microbiome test and blood test for cytokines repeated during pregnancy in the 3 arms
| Study group | Role | What they receive |
|---|---|---|
| cervicall cerclage | Experimental | to test vaginal microbiome distribution in women with cervical cerclage due to cervical incompetence in weeks: 12 14 18 26 32 Receives: Diagnostic Test: vaginal swab -microbiome test and blood test for cytokines |
| vaginal progesterone | Experimental | to test vaginal microbiome distribution in women treated with vaginal progesterone due to cervical shortening in weeks: 12 14 18 26 32 Receives: Diagnostic Test: vaginal swab -microbiome test and blood test for cytokines |
| contol | No intervention | to test vaginal microbiome during pregnancies without cerclage or progesterone |
What is being measured
The primary outcome is the main question the study is designed to answer.
vaginal microbiome distribution between the arms
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2017
- Study start26 Mar 2017
- Primary completionJan 2020 (estimated)
- Study completionJan 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Preterm LaborStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Western Galilee Hospital-Nahariya
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Maya Wolf, MD, Principal investigator, Western Galilee Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03253016
- Sponsor's protocol ID
- 0196-16-NHR
- Status last verified
- Mar 2017
- First submitted
- 14 Aug 2017
- Last updated
- 17 Aug 2017
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Aug 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Comparative Evaluation to Evaluate the Correlation Between Cervical Cerclage or Vaginal Progesterone and Maternal Vaginal Microbiome Distribution During Pregnancy
- ClinicalTrials.gov ID
- NCT03253016
- Acronym / sponsor ID
- 0196-16-NHR
- Conditions
- Preterm Labor
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Western Galilee Hospital-NahariyaOther government
- Study start
- 26 Mar 2017 (actual)
- Primary completion
- Jan 2020 (estimated)
- Study completion
- Jan 2021 (estimated)
- First posted
- 17 Aug 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A comparative evaluation to evaluate the correlation between cervical cerclage or vaginal progesterone and maternal vaginal microbiome distribution during pregnancy
Detailed description
Cervical insufficiency is primarily a clinical diagnosis, characterized by painless cervical dilation leading to recurrent second-trimester pregnancy losses/births of otherwise normal pregnancies.
Adverse perinatal events associated with cervical insufficiency include prolapse of the fetal membranes into the vagina, intra-amniotic infection, preterm premature rupture of membranes, preterm labor and fetal loss.
Congenital and acquired cervical abnormalities increase the risk of cervical insufficiency; Acquired risk factors are more common and include cervical trauma during delivery, rapid mechanical cervical dilation before a gynecologic procedure or treatment of cervical intraepithelial neoplasia (1). Congenital abnormalities include genetic disorders affecting collagen, uterine anomalies and in the past - in utero diethylstilbestrol (DES) exposure (2, 3).
The diagnosis of cervical insufficiency is based on either
- History of painless cervical dilatation with preterm (midtrimester) delivery
- History of prior second-trimester pregnancy losses or preterm births and cervical length ≤25 mm on transvaginal ultrasonography examination or advanced cervical changes on physical examination before 24 weeks of gestation.
The diagnosis of cervical insufficiency is usually limited to singleton gestations. In addition, preterm labor, infection, abruptio placenta, and bleeding placenta previa should be excluded, as these disorders could account for biochemically mediated cervical ripening leading to second-trimester pregnancy loss or preterm delivery independent of structural/anatomic cervical weakness [4].
The American College of Obstetricians and Gynecologists (ACOG) defines cervical insufficiency as the inability of the uterine cervix to retain a pregnancy in the second trimester in the absence of clinical contractions, labor, or both [5].
Women with a history of cervical insufficiency should be considered for history-indicated cerclage in future pregnancies at 12 to 14 weeks of gestation (6, 7).
Cerclage placement is considered a benign proce¬dure, the risks of such procedure include - cervical lacerations at the time of delivery, the need for cesarean delivery because of the inability of the cervix to dilate secondary to cervical scarring and dystocia, infection, cervical cerclage displacement Nonsurgical interventions have been advocated for patients with presumed cervical insufficiency. Progesterone supplementation appears to reduce the rate of spontaneous singleton preterm birth in women who have had a previous spontaneous preterm singleton birth and in women with a short cervix on ultrasound examination in the current pregnancy (8). In women with a prior preterm birth, continuing progesterone supplementation after placement of a cerclage has not been proven to be useful, but available data are limited.
Most cerclages are placed via a transvaginal approach. The transabdominal approach is more invasive, but allows higher placement, while transvaginal cerclages often end up distal to the internal os. The two most common transvaginal techniques for cerclage are McDonald procedure and Shirodkar procedure. The McDonald procedure is easier to perform and remove. The bulk of data show no significant differences in pregnancy outcome between the two procedures (6, 9, 10).
McDonald cerclage -
- The procedure is begun by grasping the anterior and posterior lips of the cervix with one or two ring forceps
- A curved needle loaded with large caliber non-absorbable synthetic suture (at least number 1 or 2 braided or monofilament) is inserted at 12 o'clock, at least 2 cm above the external os.
- Four to six passes of a purse-string suture are taken circumferentially around the entire cervix as high as safely possible.
- The two ends of the suture are then tied securely and cut, leaving the ends long enough to grasp with a clamp when it is time to remove it (11).
During gestation, the female body undergoes hormonal, immunological, and metabolic changes to support fetal growth and development. There are noticeable changes in the microbiota at different body sites during pregnancy.
The human vaginal microbiota is a key component in the defense system against microbial and viral infections. The vaginal microbiome is dominated by many species including Lactobacillus and members of the Clostridiales, Bacteriodales, and Actinomycetales. Specifically, these lactic acid producing bacteria can create a barrier against pathogen invasion by maintaining a low pH (< 4.5) and by secreting metabolites that play an important role in inhibition of bacterial and viral infection in the urogenital tract.
The vaginal microbiome undergoes significant changes during pregnancy, including a significant decrease in overall diversity, increased stability and enrichment with Lactobacillus species (12). These correlate with a decrease in the vaginal pH and an increase in vaginal secretions. Vaginal microbial compositions were found to differ according to gestational age, while the communities at the later stages of pregnancy resembled those of the non-pregnant state. The dominant Lactobacillus species in pregnancy varies according to ethnic group. In women whose vaginal microbiota is not lactobacilli-dominated anti-bacterial defense mechanisms are reduced. The enhanced proliferation of pathogenic bacteria plus degradation of the cervical barrier increase bacterial passage into the endometrium and amniotic cavity and trigger preterm myometrial contractions (13).
About 2 million cervical cerclages are performed annually to prevent preterm birth. Two types of suture material are used for cerclage: monofilament or multifilament braided. Braided sutures are most frequently used, although no evidence exists to favor them over monofilament sutures. Birth outcomes in a retrospective cohort of 678 women receiving cervical cerclage in five UK university hospitals showed that braided cerclage was associated with increased intrauterine death (15% versus 5%; P = 0.0001) and preterm birth (28% versus 17%; P = 0.0006) compared to monofilament suture. A prospective study explored the vaginal microbiome in women at risk of preterm birth because of short cervical length (≤25 mm) who received braided (n = 25) or monofilament (n = 24) cerclage under comparable circumstances (14). Braided suture induced a persistent shift toward vaginal microbiome dysbiosis characterized by reduced Lactobacillus spp. and enrichment of pathobionts. Vaginal dysbiosis was associated with inflammatory cytokine and interstitial collagenase excretion into cervicovaginal fluid and premature cervical remodeling. Monofilament suture had comparatively minimal impact upon the vaginal microbiome and its interactions with the host. The shift of the human vaginal microbiome toward dysbiosis correlated with preterm birth (14).
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| cervicall cerclage | Experimental | Diagnostic Test: vaginal swab -microbiome test and blood test for cytokinesto test vaginal microbiome distribution in women with cervical cerclage due to cervical incompetence in weeks: 12 14 18 26 32 |
| vaginal progesterone | Experimental | Diagnostic Test: vaginal swab -microbiome test and blood test for cytokinesto test vaginal microbiome distribution in women treated with vaginal progesterone due to cervical shortening in weeks: 12 14 18 26 32 |
| contol | No intervention | –to test vaginal microbiome during pregnancies without cerclage or progesterone |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- G- roup 1 - Pregnant women with a singleton gestation and cervical cerclage at 12-14 weeks of gestation due to obstetrical history characteristic of cervical insufficiency G- roup 2 - Pregnant women with a singleton gestation at 12-14 weeks of gestation without a history of cervical insufficiency
- Group 3 - Pregnant women treated with progesterone due to previous preterm labor without cerclage
Key exclusion criteria (1 listed)
- A- cute cervical insufficiency P- roven or suspected chorioamnionitis P- remature rupture of membranes F- etal structural abnormality G- estation beyond 15 weeks A- ntibiotic usage in the past month P- robiotic use in the past month R- eported autoimmune disease or immunosuppressive disorder
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| vaginal swab -microbiome test and blood test for cytokinesvaginal microbiome test and blood test for cytokines repeated during pregnancy in the 3 arms | Diagnostic test | cervicall cerclage, vaginal progesterone |
Primary outcome
vaginal microbiome distribution between the arms
Time frame: 5 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Aug 2017.
Related trials for Preterm Labor
Not yet recruiting
nCPAP-NAVA-Backup Versus Standard nCPAP for Severe Apnea in Preterm Infants ≤28 Weeks
Apnea of Prematurity
Recruiting
Study of the Influence of Intraperitoneal Insufflation of CO2 by Laparoscopy on the Short-term Evolution of Premature Infants With Ulcerative Necrotizing Enterocolitis
Preterm Birth, Enterocolitis, Necrotizing
RecruitingObservational study
Multidimensional Dynamic Early Warning System for Neonatal Necrotizing Enterocolitis: A Multicenter Clinical Study
NEC - Necrotizing Enterocolitis
Recruiting
Optimization of Saturation Targets And Resuscitation Trial (OptiSTART)
Premature Infants, Bronchopulmonary Dysplasia
RecruitingObservational study
Growing Little PEAPODS Study
Premature Birth, Premature Infant
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Maya Wolf, MD principal investigator
Western Galilee Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing vaginal swab -microbiome test and blood test for cytokines in people with Preterm Labor, run by Western Galilee Hospital-Nahariya at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 17 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Maya Wolf, MD (972-507887800, Mayaf@gmc.gov.il), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
vaginal microbiome distribution between the arms (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2017.